LASA

Lasa Supergenerics Share Price

₹22.78 +0.68 (3.08%)

22 Feb, 2025 21:29

SIP TrendupStart SIP in LASA

Start SIP

Performance

  • Low
  • ₹22
  • High
  • ₹25
  • 52 Week Low
  • ₹19
  • 52 Week High
  • ₹33
  • Open Price₹22
  • Previous Close₹22
  • Volume140,728

Investment Returns

  • Over 1 Month -17.19%
  • Over 3 Month -7.02%
  • Over 6 Month -16.06%
  • Over 1 Year -25.68%
SIP Lightning

Smart Investing Starts Here Start SIP with Lasa Supergenerics for Steady Growth!

Invest Now

Lasa Supergenerics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -7.2
  • PEG Ratio
  • -0.3
  • Market Cap Cr
  • 114
  • P/B Ratio
  • 1.2
  • Average True Range
  • 2.03
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.88
  • RSI
  • 40.64
  • MFI
  • 58

Lasa Supergenerics Financials

Lasa Supergenerics Technicals

EMA & SMA

Current Price
₹22.78
+ 0.68 (3.08%)
pointer
  • stock-down_img
  • Bearish Moving Average 14
  • stock-up_img
  • Bullish Moving Average 2
  • 20 Day
  • ₹24.13
  • 50 Day
  • ₹25.40
  • 100 Day
  • ₹25.99
  • 200 Day
  • ₹26.28

Resistance and Support

23.12 Pivot Speed
  • R3 26.57
  • R2 25.53
  • R1 24.16
  • S1 21.75
  • S2 20.71
  • S3 19.34

What's your outlook on Lasa Supergenerics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lasa Supergenerics has an operating revenue of Rs. 126.13 Cr. on a trailing 12-month basis. An annual revenue de-growth of -21% needs improvement, Pre-tax margin of -18% needs improvement, ROE of -22% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 39 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D which indicates heavy supply, Group Rank of 20 indicates it belongs to a strong industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lasa Supergenerics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-13 Quarterly Results
2025-01-28 Others Inter-alia, to consider 1. The issue of warrants. 2. Proposal of fund raising by way of equity shares through rights issue. 3. Other business matters. per share(2.5%)Final Dividend
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results

Lasa Supergenerics F&O

Lasa Supergenerics Shareholding Pattern

53.65%
0%
34.12%
12.23%

About Lasa Supergenerics

  • NSE Symbol
  • LASA
  • BSE Symbol
  • 540702
  • Chairman & Managing Director
  • Dr. Omkar Pravin Herlekar
  • ISIN
  • INE670X01014

Similar Stocks to Lasa Supergenerics

Lasa Supergenerics FAQs

Lasa Supergenerics share price is ₹22 As on 22 February, 2025 | 21:15

The Market Cap of Lasa Supergenerics is ₹114.1 Cr As on 22 February, 2025 | 21:15

The P/E ratio of Lasa Supergenerics is -7.2 As on 22 February, 2025 | 21:15

The PB ratio of Lasa Supergenerics is 1.2 As on 22 February, 2025 | 21:15

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23